Bristol-Myers Squibb Co

BMY: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
m$qLOCK|x$LOCK|<?$qyb<

Bristol-Myers' New Drug Launches Are Progressing Slowly but Still Hold Significant Potential

Business Strategy and Outlook

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. We believe the strong overall pipeline helps support its wide moat.

Sponsor Center